Provided by Tiger Trade Technology Pte. Ltd.

RxSIGHT, INC.

6.44
-0.3000-4.45%
Post-market: 6.440.00000.00%18:03 EDT
Volume:1.08M
Turnover:7.06M
Market Cap:264.79M
PE:-6.78
High:6.87
Open:6.78
Low:6.35
Close:6.74
52wk High:27.13
52wk Low:6.32
Shares:41.12M
Float Shares:32.44M
Volume Ratio:2.32
T/O Rate:3.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9500
EPS(LYR):-0.9533
ROE:-13.99%
ROA:-9.56%
PB:0.96
PE(LYR):-6.76

Loading ...

RxSight amends CFO appointment filing to disclose USD 169,348 sign-on bonus

Reuters
·
Mar 20

RxSight Earnings Call: Strong Core, Cautious Outlook

TIPRANKS
·
Mar 09

Analysts Have Conflicting Sentiments on These Healthcare Companies: Silence Therapeutics (SLN), RxSight (RXST) and Compass Therapeutics (CMPX)

TIPRANKS
·
Mar 06

Analysts Have Conflicting Sentiments on These Healthcare Companies: Phathom Pharmaceuticals (PHAT), BioLife Solutions (BLFS) and RxSight (RXST)

TIPRANKS
·
Feb 27

UBS Adjusts Price Target on RxSight to $9 From $8, Maintains Neutral Rating

MT Newswires Live
·
Feb 26

RxSight price target raised to $9 from $8 at UBS

TIPRANKS
·
Feb 26

RxSight Price Target Maintained With a $13.00/Share by Needham

Dow Jones
·
Feb 26

Wells Fargo Remains a Hold on RxSight (RXST)

TIPRANKS
·
Feb 26

Rxsight Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Feb 26

RxSight Q4 revenue falls 19% on lower LDD sales

Reuters
·
Feb 26

RxSight Q4 Adj. EPS $(0.03) Beats $(0.33) Estimate, Sales $32.607M Beat $30.117M Estimate

Benzinga
·
Feb 26

BRIEF-Rxsight Q4 Gross Profit USD 25.3 Million

Reuters
·
Feb 26

Rxsight Outlook FY Revenue USD 120-135 Million

THOMSON REUTERS
·
Feb 26

Press Release: RXSight, Inc. Reports Fourth Quarter and 2025 Results; Issues 2026 Guidance

Dow Jones
·
Feb 26

Rxsight Inc expected to post a loss of 33 cents a share - Earnings Preview

Reuters
·
Feb 24

Analysts Offer Insights on Healthcare Companies: RxSight (RXST), Senseonics Holdings (SENS) and Novo Nordisk (NVO)

TIPRANKS
·
Feb 21

RxSight Inc. Files Initial Statement of Beneficial Ownership for Chief Financial Officer Mark Wilterding

Reuters
·
Jan 31

William Blair Initiates Coverage on RxSight With Market Perform

MT Newswires Live
·
Jan 30

RxSight Is Maintained at Neutral by Piper Sandler

Dow Jones
·
Jan 20

RxSight price target raised to $11 from $10 at Piper Sandler

TIPRANKS
·
Jan 20